• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性肠病的循证临床实践指南。

Evidence-based clinical practice guidelines for inflammatory bowel disease.

机构信息

Guidelines Committee for Creating and Evaluating the ''Evidence-Based Clinical Practice Guidelines for Inflammatory Bowel Disease in Japan'', The Japanese Society of Gastroenterology (JSGE), 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.

Ofuna Central Hospital, 6-2-24 Ofuna, Kamakura-shi, Kanagawa, 247-0056, Japan.

出版信息

J Gastroenterol. 2018 Mar;53(3):305-353. doi: 10.1007/s00535-018-1439-1. Epub 2018 Feb 10.

DOI:10.1007/s00535-018-1439-1
PMID:29429045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5847182/
Abstract

Inflammatory bowel disease (IBD) is a chronic disorder involving mainly the intestinal tract, but possibly other gastrointestinal and extraintestinal organs. Although etiology is still uncertain, recent knowledge in pathogenesis has accumulated, and novel diagnostic and therapeutic modalities have become available for clinical use. Therefore, the previous guidelines were urged to be updated. In 2016, the Japanese Society of Gastroenterology revised the previous versions of evidence-based clinical practice guidelines for ulcerative colitis (UC) and Crohn's disease (CD) in Japanese. A total of 59 clinical questions for 9 categories (1. clinical features of IBD; 2. diagnosis; 3. general consideration in treatment; 4. therapeutic interventions for IBD; 5. treatment of UC; 6. treatment of CD; 7. extraintestinal complications; 8. cancer surveillance; 9. IBD in special situation) were selected, and a literature search was performed for the clinical questions with use of the MEDLINE, Cochrane, and Igaku Chuo Zasshi databases. The guidelines were developed with the basic concept of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Recommendations were made using Delphi rounds. This English version was produced and edited based on the existing updated guidelines in Japanese.

摘要

炎症性肠病(IBD)是一种主要累及肠道的慢性疾病,但也可能累及其他胃肠道和肠外器官。尽管病因仍不确定,但发病机制的最新知识不断积累,新的诊断和治疗方法也已可用于临床。因此,需要更新以前的指南。2016 年,日本消化病学会修订了以前的溃疡性结肠炎(UC)和克罗恩病(CD)循证临床实践指南的日语文本。共选择了 9 个类别中的 59 个临床问题(1. IBD 的临床特征;2. 诊断;3. 治疗中的一般考虑;4. IBD 的治疗干预;5. UC 的治疗;6. CD 的治疗;7. 肠外并发症;8. 癌症监测;9. 特殊情况下的 IBD),并使用 MEDLINE、Cochrane 和 Igaku Chuo Zasshi 数据库对有临床意义的问题进行文献检索。指南的制定基于推荐评估、制定和评估(GRADE)系统的基本概念。采用 Delphi 轮次进行推荐。本英文版本是基于现有的日语文本更新指南制作和编辑的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/63c7e247cbed/535_2018_1439_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/dca0c1c20929/535_2018_1439_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/0e49625c1fb9/535_2018_1439_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/4c1f8fdc647d/535_2018_1439_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/6e94a5d70dd2/535_2018_1439_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/9b3cb1c1ea7d/535_2018_1439_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/b644b1437684/535_2018_1439_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/813418870182/535_2018_1439_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/3dad09fd9ac9/535_2018_1439_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/63c7e247cbed/535_2018_1439_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/dca0c1c20929/535_2018_1439_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/0e49625c1fb9/535_2018_1439_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/4c1f8fdc647d/535_2018_1439_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/6e94a5d70dd2/535_2018_1439_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/9b3cb1c1ea7d/535_2018_1439_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/b644b1437684/535_2018_1439_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/813418870182/535_2018_1439_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/3dad09fd9ac9/535_2018_1439_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6466/5847182/63c7e247cbed/535_2018_1439_Fig9_HTML.jpg

相似文献

1
Evidence-based clinical practice guidelines for inflammatory bowel disease.炎症性肠病的循证临床实践指南。
J Gastroenterol. 2018 Mar;53(3):305-353. doi: 10.1007/s00535-018-1439-1. Epub 2018 Feb 10.
2
Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt.埃及开罗炎症性肠病的流行病学和临床特征
World J Gastroenterol. 2014 Jan 21;20(3):814-21. doi: 10.3748/wjg.v20.i3.814.
3
Inflammatory Bowel Diseases and Spondyloarthropathies.炎症性肠病和脊柱关节病
J Rheumatol Suppl. 2015 Nov;93:21-3. doi: 10.3899/jrheum.150628.
4
Inflammatory bowel disease. Part II: Clinical and therapeutic aspects.炎症性肠病。第二部分:临床与治疗方面。
Dis Mon. 1991 Nov;37(11):669-746. doi: 10.1016/s0011-5029(05)80013-6.
5
Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD.选择炎症性肠病的疾病修正试验终点:IOIBD 的 SPIRIT 共识。
Gastroenterology. 2021 Apr;160(5):1452-1460.e21. doi: 10.1053/j.gastro.2020.10.065. Epub 2021 Jan 6.
6
Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93.溃疡性结肠炎和克罗恩病诊断后第一年的临床病程。1990 - 1993年挪威东南部一项基于人群的大型前瞻性研究结果。
Scand J Gastroenterol. 1997 Oct;32(10):1005-12. doi: 10.3109/00365529709011217.
7
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia.亚洲克罗恩病和结肠炎组织与亚太消化病学会炎症性肠病亚洲地区医学管理和监测实践建议。
J Gastroenterol Hepatol. 2021 Mar;36(3):637-645. doi: 10.1111/jgh.15185. Epub 2020 Jul 29.
8
Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation.炎症性肠病的诊断与治疗:泛美克罗恩病和结肠炎组织首个拉丁美洲共识
Rev Gastroenterol Mex. 2017 Jan-Mar;82(1):46-84. doi: 10.1016/j.rgmx.2016.07.003. Epub 2016 Dec 13.
9
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.2020 年炎症性肠病循证临床实践指南。
J Gastroenterol. 2021 Jun;56(6):489-526. doi: 10.1007/s00535-021-01784-1. Epub 2021 Apr 22.
10
Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.儿童及青年溃疡性结肠炎与克罗恩病的鉴别:北美儿科胃肠病学、肝病学和营养学会及美国克罗恩病和结肠炎基金会工作组报告
J Pediatr Gastroenterol Nutr. 2007 May;44(5):653-74. doi: 10.1097/MPG.0b013e31805563f3.

引用本文的文献

1
Biotin/sulfasalazine combination therapy alleviates acetic acid-induced ulcerative colitis in rats via modulation of S1PR1/NF-κB/IL-23/STAT3/COX-2 axis.生物素/柳氮磺胺吡啶联合疗法通过调节S1PR1/NF-κB/IL-23/STAT3/COX-2轴减轻大鼠乙酸诱导的溃疡性结肠炎。
Sci Rep. 2025 Jul 25;15(1):27037. doi: 10.1038/s41598-025-09932-w.
2
Role of the Dietitian in the Inflammatory Bowel Disease Multidisciplinary Team.营养师在炎症性肠病多学科团队中的作用。
J Gastroenterol Hepatol. 2025 Sep;40(9):2190-2196. doi: 10.1111/jgh.70001. Epub 2025 Jul 10.
3
Expert consensus on diagnostic guidelines for pediatric inflammatory bowel disease in Japan.

本文引用的文献

1
Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study.抗 TNF 治疗与炎症性肠病患者皮肤病变特征的相关性:一项队列研究。
Ann Intern Med. 2016 Jan 5;164(1):10-22. doi: 10.7326/M15-0729. Epub 2015 Dec 8.
2
Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis.美沙拉嗪而非柳氮磺胺吡啶可降低炎症性肠病患者结直肠肿瘤的风险:一项特定药物的系统评价和荟萃分析。
Inflamm Bowel Dis. 2015 Nov;21(11):2562-9. doi: 10.1097/MIB.0000000000000540.
3
日本小儿炎症性肠病诊断指南专家共识
J Gastroenterol. 2025 Jul 2. doi: 10.1007/s00535-025-02271-7.
4
Current and forecasted 10-year prevalence and incidence of inflammatory bowel disease in Hong Kong, Japan, and the United States.香港、日本和美国炎症性肠病的当前及预测的10年患病率和发病率。
World J Gastroenterol. 2025 May 14;31(18):105472. doi: 10.3748/wjg.v31.i18.105472.
5
Efficacy and Safety of Vedolizumab with Glucocorticoids vs Infliximabin Severe Ulcerative Colitis: A Retrospective Study.维多珠单抗联合糖皮质激素与英夫利昔单抗治疗重度溃疡性结肠炎的疗效和安全性:一项回顾性研究
Int J Gen Med. 2025 Jun 3;18:2839-2849. doi: 10.2147/IJGM.S525638. eCollection 2025.
6
Decorating probiotics with a triggerable and catalytic shell for synergistically enhanced colitis biotherapy.用可触发且具有催化作用的外壳修饰益生菌以协同增强结肠炎生物疗法。
Mater Today Bio. 2025 May 12;32:101861. doi: 10.1016/j.mtbio.2025.101861. eCollection 2025 Jun.
7
History of Previous Medication Self-Discontinuation Predicts the Current Adherence to 5-Aminosalicylates in Patients With Ulcerative Colitis.既往自行停药史可预测溃疡性结肠炎患者当前对5-氨基水杨酸类药物的依从性。
JGH Open. 2025 May 20;9(5):e70181. doi: 10.1002/jgh3.70181. eCollection 2025 May.
8
Explainable artificial intelligence for prediction of refractory ulcerative colitis: analysis of a Japanese Nationwide Registry.用于预测难治性溃疡性结肠炎的可解释人工智能:一项日本全国性登记研究分析
Ann Med. 2025 Dec;57(1):2499960. doi: 10.1080/07853890.2025.2499960. Epub 2025 May 5.
9
Inflammation-Associated Carcinogenesis in Inflammatory Bowel Disease: Clinical Features and Molecular Mechanisms.炎症性肠病中的炎症相关致癌作用:临床特征与分子机制
Cells. 2025 Apr 9;14(8):567. doi: 10.3390/cells14080567.
10
Complete mucosal healing prevents stricture progression after endoscopic balloon dilation in Crohn's disease.在克罗恩病中,完全黏膜愈合可防止内镜下球囊扩张术后狭窄进展。
DEN Open. 2025 Apr 23;5(1):e70121. doi: 10.1002/deo2.70121. eCollection 2025 Apr.
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions.
炎症性肠病中疾病严重程度的定义:现状与未来方向。
Clin Gastroenterol Hepatol. 2016 Mar;14(3):348-354.e17. doi: 10.1016/j.cgh.2015.06.001. Epub 2015 Jun 11.
4
Budesonide for induction of remission in Crohn's disease.布地奈德用于诱导克罗恩病缓解
Cochrane Database Syst Rev. 2015 Jun 3;2015(6):CD000296. doi: 10.1002/14651858.CD000296.pub4.
5
Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.系统评价与荟萃分析:在先前抗 TNF 治疗失败的炎症性肠病患者中使用第二种抗 TNF 的疗效。
Aliment Pharmacol Ther. 2015 Apr;41(7):613-23. doi: 10.1111/apt.13083. Epub 2015 Feb 4.
6
The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease.第二次欧洲炎症性肠病生殖与妊娠的循证共识。
J Crohns Colitis. 2015 Feb;9(2):107-24. doi: 10.1093/ecco-jcc/jju006.
7
Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.接受阿达木单抗或英夫利昔单抗维持治疗的门诊溃疡性结肠炎原发性抗TNF应答者继发性应答丧失率相似。
J Clin Gastroenterol. 2015 Sep;49(8):675-82. doi: 10.1097/MCG.0000000000000265.
8
Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID.抗 TNF 治疗的克罗恩病患者肠外瘘的长期结局:GETAID 的队列研究。
Am J Gastroenterol. 2014 Sep;109(9):1443-9. doi: 10.1038/ajg.2014.183. Epub 2014 Aug 5.
9
A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease.全球共识:肛门周围瘘管型克罗恩病的分类、诊断和多学科治疗。
Gut. 2014 Sep;63(9):1381-92. doi: 10.1136/gutjnl-2013-306709. Epub 2014 Jun 20.
10
Guidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2014 edition.日本产科诊疗指南:日本妇产科学会(JSOG)及日本妇产科医师协会(JAOG)2014年版
J Obstet Gynaecol Res. 2014 Jun;40(6):1469-99. doi: 10.1111/jog.12419.